drugset / Trial / NCT01984255

A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients

NCT01984255

Phase 1 Terminated 3 enrolled University of Texas Southwestern Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Open label, two-arm, randomized, two agent, single center trial.

Timeline

Start
2014-04
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bavituximab Monoclonal antibody 3 mg/kg Intravenous
Subject Ipilimumab Monoclonal antibody 3 mg/kg Intravenous

Indications